Loading clinical trials...
Loading clinical trials...
A Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
Conditions
Interventions
UCB0599
Placebo
Locations
6
United States
Up0077 102
Long Beach, California, United States
Up0077 103
Bay Harbor Islands, Florida, United States
Up0077 105
DeLand, Florida, United States
Up0077 107
Atlanta, Georgia, United States
Up0077 101
Farmington Hills, Michigan, United States
Up0077 104
Raleigh, North Carolina, United States
Start Date
May 6, 2019
Primary Completion Date
February 19, 2020
Completion Date
February 19, 2020
Last Updated
May 6, 2021
NCT07330258
NCT06508801
NCT07384429
NCT02119611
NCT07310264
NCT07216976
Lead Sponsor
UCB Biopharma S.P.R.L.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions